Mohamad Tareq Muhandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamad Tareq Muhandes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alma Osmanovic
Department of Neurology Hannover Medical School Hannover Germany
1 shared publication - Benedikt Becker
Department of Neurology, Klinikum rechts der Isar, School of Medicine Technical University of Munich Munich Germany
1 shared publication - Bogdan Bjelica
Department of Neurology Hannover Medical School Hannover Germany
1 shared publication - Camilla Wohnrade
Department of Neurology, Hannover Medical School, Hannover, Germany
1 shared publication - Charlotte Vogt
Neuromuscular Disease Unit/ALS Clinic St. Gallen Switzerland
1 shared publication Christoph Neuwirth
Neuromuscular Disease Unit/ALS Clinic St. Gallen Switzerland
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70405
Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study
Background: This study aimed to evaluate changes in compound muscle action potential (CMAP) amplitude in adults with spinal muscular atrophy (SMA) undergoing nusinersen treatment and its association with motor function improvements. Methods: This multicenter study assessed median, ulnar, and peroneal CMAP over a follow‐up of up to 4.5 years using linear mixed models. Motor function was measured using the Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale Expanded (HFMSE). Correlations between CMAP and motor function scores were analyzed. Results: Seventy‐eight patients (27 ambulatory, 51 non‐ambulatory) were included. Baseline ulnar CMAP ≥ 2.0 mV distinguished SMA type 3 from type 2 with 91.3% sensitivity and 88.9% specificity (AUC 0.96, 95% CI 0.92–1.0), while baseline median nerve CMAP ≥ 6.5 mV showed 91.7% sensitivity and 77.3% specificity (AUC 0.84, 95% CI 0.72–0.96). No significant changes over time were observed in median, ulnar, and peroneal CMAP amplitudes ( p > 0.05). CMAP trajectories did not differ between SMA types 2 and 3 ( p > 0.05). No significant difference in the change in RULM or HFMSE at any time point was observed between SMA patients with baseline median nerve CMAP < 5 mV and those with CMAP of ≥ 5 mV ( p > 0.05). No significant correlations were found between changes in median nerve CMAP and HFMSE or RULM ( p > 0.05). Discussion: CMAP amplitudes remained stable during nusinersen treatment, with no differences in trajectories between SMA types 2 and 3. Our findings suggest that while CMAP amplitude correlates with disease severity, it may not serve as a sensitive biomarker of treatment response in adult SMA patients.
- 1 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70405
Open AccessCompound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q‐Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study
Background: This study aimed to evaluate changes in compound muscle action potential (CMAP) amplitude in adults with spinal muscular atrophy (SMA) undergoing nusinersen treatment and its association with motor function improvements. Methods: This multicenter study assessed median, ulnar, and peroneal CMAP over a follow‐up of up to 4.5 years using linear mixed models. Motor function was measured using the Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale Expanded (HFMSE). Correlations between CMAP and motor function scores were analyzed. Results: Seventy‐eight patients (27 ambulatory, 51 non‐ambulatory) were included. Baseline ulnar CMAP ≥ 2.0 mV distinguished SMA type 3 from type 2 with 91.3% sensitivity and 88.9% specificity (AUC 0.96, 95% CI 0.92–1.0), while baseline median nerve CMAP ≥ 6.5 mV showed 91.7% sensitivity and 77.3% specificity (AUC 0.84, 95% CI 0.72–0.96). No significant changes over time were observed in median, ulnar, and peroneal CMAP amplitudes ( p > 0.05). CMAP trajectories did not differ between SMA types 2 and 3 ( p > 0.05). No significant difference in the change in RULM or HFMSE at any time point was observed between SMA patients with baseline median nerve CMAP < 5 mV and those with CMAP of ≥ 5 mV ( p > 0.05). No significant correlations were found between changes in median nerve CMAP and HFMSE or RULM ( p > 0.05). Discussion: CMAP amplitudes remained stable during nusinersen treatment, with no differences in trajectories between SMA types 2 and 3. Our findings suggest that while CMAP amplitude correlates with disease severity, it may not serve as a sensitive biomarker of treatment response in adult SMA patients.